- Home
- QMCO vs IMRN Comparison
QMCO vs IMRN Comparison
Compare QMCO & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QMCO
- IMRN
- Stock Information
- Founded
- QMCO 1980
- IMRN 1994
- Country
- QMCO United States
- IMRN Australia
- Employees
- QMCO N/A
- IMRN N/A
- Industry
- QMCO Electronic Components
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- QMCO Technology
- IMRN Health Care
- Exchange
- QMCO Nasdaq
- IMRN Nasdaq
- Market Cap
- QMCO 98.8M
- IMRN 9.2M
- IPO Year
- QMCO N/A
- IMRN N/A
- Fundamental
- Price
- QMCO $8.27
- IMRN $1.83
- Analyst Decision
- QMCO Hold
- IMRN Strong Buy
- Analyst Count
- QMCO 2
- IMRN 1
- Target Price
- QMCO $19.00
- IMRN $5.00
- AVG Volume (30 Days)
- QMCO 710.6K
- IMRN 43.6K
- Earning Date
- QMCO 09-10-2025
- IMRN 08-29-2025
- Dividend Yield
- QMCO N/A
- IMRN N/A
- EPS Growth
- QMCO N/A
- IMRN N/A
- EPS
- QMCO N/A
- IMRN N/A
- Revenue
- QMCO $266,079,000.00
- IMRN $4,777,422.00
- Revenue This Year
- QMCO $7.49
- IMRN N/A
- Revenue Next Year
- QMCO $3.22
- IMRN N/A
- P/E Ratio
- QMCO N/A
- IMRN N/A
- Revenue Growth
- QMCO N/A
- IMRN 48.63
- 52 Week Low
- QMCO $2.88
- IMRN $1.50
- 52 Week High
- QMCO $90.64
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- QMCO 52.86
- IMRN 50.67
- Support Level
- QMCO N/A
- IMRN $1.80
- Resistance Level
- QMCO $7.87
- IMRN $1.94
- Average True Range (ATR)
- QMCO 0.41
- IMRN 0.07
- MACD
- QMCO -0.18
- IMRN -0.00
- Stochastic Oscillator
- QMCO 95.94
- IMRN 42.11
About QMCO Quantum Corporation
Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data in the era of artificial intelligence (AI). It provides one of the comprehensive and cost-efficient solutions for the entire data lifecycle. The group provides solutions for video, images, audio, and other large files because this unstructured data represents. Its portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The group operates in three geographic regions: Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC).
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.